NCT01888224已完成1 期
Open Label, Balanced, Randomized, Two-treatment, Two-period, Two Sequence, Single Dose, Crossover, Oral Bioequivalence Study of Isotretinoin Capsules 40 mg of Dr. Reddy's Laboratories Limited, India Comparing With Amnesteem Capsules 40 mg of Mylan Pharmaceuticals Inc., in Healthy, Adult, Male Human Subjects Under Fed Conditions.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 61
- 试验地点
- 1
- 主要终点
- Area under curve (AUC)
研究概览
简要总结
To characterise the pharmacokinetic profile of sponsor's test formulation Isotretinoin Capsules 40 mg in comparison to the reference formulation Amnesteem (Containing Isotretinoin) Capsules 40 mg after single oral dose administration to healthy, normal, adult, human male subjects under fed condition.
详细描述
An open label, balanced, randomized, two-treatment, two-period, two sequence, single dose, crossover, oral bioequivalence study of Isotretinoin Capsules 40 mg under fed conditions.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy adult human male volunteers between 18 to 45 years of age (both inclusive) living in and around Ahmedabad city or western part of India.
- •Having a Body Mass Index (BMI) between 18.5-27.5 (both inclusive), calculated as weight in kg / height in meter
- •Not having any significant disease in medical history or clinically significant abnormal findings during screening, medical history, physical examination,laboratory evaluations, 12- lead ECG and X-ray chest recordings.
- •Able to understand and comply with the study procedures, in the opinion of the principal investigator.
- •Able to comply to use 2 forms of effective contraception methods simultaneously during Isotretinoin study, and for 1 month after study.
- •Able to give voluntary written informed consent for participation in the trial.
- •Able to read and/or understand drug medication Guide either in English or in a provided translation when given along with informed consent form.
- •Exclusion Criteria
- •Known hypersensitivity or idiosyncratic reaction to Isotretinoin or any of the excipients including parabens or any related drug.
- •History or presence of any disease or condition which might compromise the haemopoietic, renal, hepatic, endocrine, pulmonary, central nervous, cardiovascular, immunological, dermatological, gastrointestinal or any other body system.
- •Ingestion of any medicine including herbal medicines at any time within 14 days before dosing in Period I. In any such case subject selection will be at the discretion of the Principal Investigator.
- •Any history or presence of asthma (including aspirin induced asthma) or nasal polyp or NSAID induced urticaria.
- •Use of any recreational drugs or history of drug addiction or testing positive in prestudy drug scans.
- •A recent history of harmful use of alcohol(less than 2 years), i.e. alcohol consumption of more than 14 standard drinks per week (A standard drink is defined as 360 ml of beer or 150 ml of wine or 45 ml of 40% distilled spirits, such as rum,whisky, brandy etc) or consumption of alcohol or alcoholic products within 48 hours prior to receiving study medicine.
- •Smokers, who smoke 10 or more than 10 cigarettes / day or inability to abstain from smoking during the study.
- •The presence of clinically significant abnormal laboratory values during screening.
- •History or presence of psychiatric disorders.
- •A history of difficulty in donating blood.
- •Donation of blood (1 unit or 350 mL) or receipt of an investigational medicinal product or participation in a drug research study within a period of 90 days prior to the first dose of study medication. Elimination half-life of the study drug should be taken into consideration for inclusion of the subject in the study.
排除标准
- 未提供
研究组 & 干预措施
Isotretinoin capsules, 40 mg
Experimental
Isotretinoin Capsules, 40 mg of Dr.Reddy's Laboratories Ltd
干预措施: Isotretinoin (Drug)
AMNESTEEM
Active Comparator
AMNESTEEM 40 mg of Mylan Pharmaceuticals Inc
干预措施: Isotretinoin (Drug)
结局指标
主要结局
Area under curve (AUC)
时间窗: Pre-dose (0) and 0.5, 1,1.5,2,2.5,3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8,10,12,16,20,24, 36, 48,72 and 96 hrs
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Bioequivalence Study of Mycophenolate Mofetil 500 mg Tablets of Dr.Reddy's Laboratories Limited Under Non-Fasting ConditionsFEDNCT01283867Dr. Reddy's Laboratories Limited92
已完成
1 期
Bioequivalence Study of Mycophenolate Mofetil 500 mg Tablets of Dr.Reddy's Laboratories Limited Under Fasting ConditionsFastingNCT01283841Dr. Reddy's Laboratories Limited48
已完成
1 期
Bioequivalence Study of Two Products of Apixaban 5mg Tablets in Healthy, Adult, Human SubjectsAntithrombic DrugNCT06043297Humanis Saglık Anonim Sirketi30
已完成
2 期
Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed ConditionsChronic Myeloid LeukemiaGastrointestinal Stromal TumorNCT02103322Amneal Pharmaceuticals, LLC48
已完成
1 期
Bioequivalence Study of Clopidogrel Tablets 300 mg Under Fed ConditionsHealthyNCT01621763Dr. Reddy's Laboratories Limited68